Kymera Therapeutics (NASDAQ:KYMR) CFO Sells $417,543.50 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce Jacobs sold 4,895 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the completion of the transaction, the chief financial officer owned 232,588 shares of the company’s stock, valued at $19,839,756.40. This represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kymera Therapeutics Trading Down 0.0%

KYMR stock opened at $83.49 on Friday. The firm has a 50 day moving average of $78.80 and a 200-day moving average of $66.80. The firm has a market capitalization of $6.82 billion, a P/E ratio of -22.69 and a beta of 2.20. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same period in the prior year, the business earned ($0.88) earnings per share. The company’s revenue for the quarter was down 60.8% compared to the same quarter last year. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Citigroup lifted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Oppenheimer increased their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Piper Sandler lifted their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Finally, B. Riley Financial upped their price objective on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $119.50.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its stake in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. grew its position in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after acquiring an additional 815 shares in the last quarter.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.